WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
On 17 November 2022, the CJEU delivered essentially two decisions on the parallel trade of medicines. The first concerned the rebranding of generic medicines to the branded reference medicine (in joined cases C-253/20 and C-254/20), and about which we published a blog on 24 November 2022. The second addressed the impact of anti-tampering devices on the possibility, and objective necessity, to rebox (in C-224/20 and C-147/20), and about which we published a blog on 2 December 2022.
Contact
Recommended articles
Hospital mergers no longer subject to the Belgian Competition Authority’s prior review
The legislator has now had the last word, by providing that, in principle, hospital mergers are no longer subject to the BCA’s prior review and approval.
Read on
WEBINAR VIDEO | When are IP holders liable for enforcing an IP right?
During this IP Update, Sofie Thijssen and Kirian Claeyé revisit when IP holders may be held liable for enforcing provisional measures based on their IP right.
Read on
EU citizens rally for medical cannabis but face a rigid European Commission
In the EU, access to medical cannabis is a matter of national policy. A group of citizens wants to change that by leveraging a citizens’ initiative and prompting the European Commission to act.
Read on